Loading...

Therapeutics

DB:P91
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
P91
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
P91 Share Price and Events
7 Day Returns
-8.6%
DB:P91
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
47.8%
DB:P91
-10.2%
DE Biotechs
-6%
DE Market
P91 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Therapeutics (P91) -8.6% -9.8% 3.4% 47.8% 325% 138.2%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • P91 outperformed the Biotechs industry which returned -10.2% over the past year.
  • P91 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
P91
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Therapeutics.

DB:P91 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:P91
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (7.26%))
1.356
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.36
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.356 * 5.96%)
8.31%

Discounted Cash Flow Calculation for DB:P91 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:P91 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.31%)
2019 -80.80 Analyst x4 -74.60
2020 -2.63 Analyst x3 -2.24
2021 44.03 Analyst x4 34.65
2022 193.95 Analyst x2 140.95
2023 264.20 Analyst x2 177.27
2024 321.13 Est @ 21.55% 198.95
2025 369.79 Est @ 15.15% 211.52
2026 409.27 Est @ 10.68% 216.15
2027 440.14 Est @ 7.54% 214.62
2028 463.67 Est @ 5.35% 208.75
Present value of next 10 years cash flows $1,326.02
DB:P91 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $463.67 × (1 + 0.23%) ÷ (8.31% – 0.23%)
$5,752.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,752.09 ÷ (1 + 8.31%)10
$2,589.69
DB:P91 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,326.02 + $2,589.69
$3,915.71
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,915.71 / 58.40
$67.05
DB:P91 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:P91 represents 0.85536x of NasdaqGS:PTCT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85536x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 67.05 x 0.85536
€57.35
Value per share (EUR) From above. €57.35
Current discount Discount to share price of €30.87
= -1 x (€30.87 - €57.35) / €57.35
46.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Therapeutics is available for.
Intrinsic value
46%
Share price is €30.87 vs Future cash flow value of €57.35
Current Discount Checks
For Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:P91 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.75
NasdaqGS:PTCT Share Price ** NasdaqGS (2019-04-18) in USD $36.09
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Therapeutics.

DB:P91 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:PTCT Share Price ÷ EPS (both in USD)

= 36.09 ÷ -2.75

-13.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Therapeutics's expected growth come at a high price?
Raw Data
DB:P91 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
63.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Therapeutics's assets?
Raw Data
DB:P91 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $6.93
NasdaqGS:PTCT Share Price * NasdaqGS (2019-04-18) in USD $36.09
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:P91 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:PTCT Share Price ÷ Book Value per Share (both in USD)

= 36.09 ÷ 6.93

5.21x

* Primary Listing of Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Therapeutics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Therapeutics expected to grow at an attractive rate?
  • Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:P91 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:P91 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 63.7%
DB:P91 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 21.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:P91 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:P91 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 803 309 257 4
2022-12-31 655 274 161 4
2021-12-31 512 59 6 6
2020-12-31 444 40 -38 7
2019-12-31 315 -54 -140 8
DB:P91 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 265 -28 -128
2018-09-30 256 9 -78
2018-06-30 245 -10 -61
2018-03-31 224 3 -69
2017-12-31 194 -10 -79
2017-09-30 142 -45 -107
2017-06-30 123 -53 -108
2017-03-31 90 -91 -130
2016-12-31 83 -104 -142
2016-09-30 70 -121 -166
2016-06-30 57 -124 -174
2016-03-31 48 -129 -174

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:P91 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:P91 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.23 5.23 3.38 3.00
2022-12-31 2.72 3.53 1.46 3.00
2021-12-31 0.54 2.71 -0.91 6.00
2020-12-31 -0.92 1.12 -2.59 7.00
2019-12-31 -2.65 -1.24 -3.85 7.00
DB:P91 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.75
2018-09-30 -1.77
2018-06-30 -1.40
2018-03-31 -1.69
2017-12-31 -2.02
2017-09-30 -2.87
2017-06-30 -3.05
2017-03-31 -3.81
2016-12-31 -4.17
2016-09-30 -4.89
2016-06-30 -5.14
2016-03-31 -5.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:P91 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 264.73 -128.08 151.85
2018-09-30 256.43 -78.48 138.87
2018-06-30 244.69 -61.25 133.42
2018-03-31 223.91 -69.21 128.74
2017-12-31 194.39 -79.00 121.27
2017-09-30 141.55 -107.07 108.36
2017-06-30 122.69 -108.50 100.59
2017-03-31 90.36 -129.93 95.09
2016-12-31 82.71 -142.11 97.13
2016-09-30 70.25 -166.26 98.85
2016-06-30 57.04 -174.32 96.56
2016-03-31 48.18 -173.77 90.40
2015-12-31 36.77 -170.45 82.08
2015-09-30 36.69 -146.77 74.21
2015-06-30 28.61 -130.83 63.37
2015-03-31 23.51 -117.57 54.90
2014-12-31 25.25 -93.75 44.82
2014-09-30 17.00 -84.37 34.29
2014-06-30 31.59 -61.51 30.44
2014-03-31 36.77 -50.99 28.30
2013-12-31 34.70 -66.43 25.22
2013-09-30 36.93 -48.35 20.96
2013-06-30 27.83 -51.23 18.06
2013-03-31 28.56 -28.57 14.63
2012-12-31 33.95 0.73 14.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Therapeutics Company Filings, last reported 3 months ago.

DB:P91 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 350.73 153.01 227.59
2018-09-30 386.09 150.93 249.40
2018-06-30 267.40 148.87 296.11
2018-03-31 150.31 146.88 178.27
2017-12-31 156.44 144.97 191.25
2017-09-30 145.88 143.09 169.31
2017-06-30 169.73 141.24 181.07
2017-03-31 100.83 99.90 202.58
2016-12-31 119.58 98.22 231.67
2016-09-30 140.18 96.56 248.34
2016-06-30 165.62 94.94 272.89
2016-03-31 196.00 93.37 298.71
2015-12-31 226.00 91.85 338.93
2015-09-30 269.15 93.20 371.52
2015-06-30 248.58 0.00 255.22
2015-03-31 273.32 0.00 280.47
2014-12-31 298.47 0.00 315.24
2014-09-30 201.30 0.00 209.39
2014-06-30 223.76 0.00 226.86
2014-03-31 244.34 0.01 246.59
2013-12-31 136.54 0.05 142.47
2013-09-30 151.03 0.08 157.23
2013-06-30 152.92 2.75 165.68
2013-03-31 34.08 3.84 54.75
2012-12-31 -18.82 4.88 2.73
  • Therapeutics's level of debt (43.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 43.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -60.8% each year.
X
Financial health checks
We assess Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Therapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:P91 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:P91 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Therapeutics has not reported any payouts.
  • Unable to verify if Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stuart Peltz
COMPENSATION $2,172,683
AGE 58
TENURE AS CEO 21.3 years
CEO Bio

Dr. Stuart W. Peltz, Ph.D co-founded PTC Therapeutics Inc. in 1998 and has been its Chief Executive Officer since 1998. Dr. Peltz served as the President of PTC Therapeutics Inc. from 1998 to April 2012. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the University of Medicine and Dentistry of New Jersey. He has been an Executive Director of PTC Therapeutics, Inc. since 1998. He served as Chairman of BioNJ Inc. until February 9, 2017 and serves as its Trustee. He served as a Director and Member of Emerging Companies Section Governing Board at Biotechnology Industry Organization (BIO). Dr. Peltz is a leader in the investigation of mRNA turnover and translation. Dr. Peltz serves on National Institutes of Health and American Cancer Society review committees and is an author of several publications in the field of his expertise. Dr. Peltz has published over 80 publications in the area of post-transcriptional control processes. He received his Ph.D. at the McArdle Laboratory for Cancer Research at the University of Wisconsin.

CEO Compensation
  • Stuart's compensation has been consistent with company performance over the past year.
  • Stuart's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Therapeutics management team in years:

1.9
Average Tenure
54.5
Average Age
  • The average tenure for the Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Stuart Peltz

TITLE
Co-Founder
COMPENSATION
$2M
AGE
58
TENURE
21.3 yrs

Allan Jacobson

TITLE
Co-Founder
COMPENSATION
$223K
AGE
72

Christine Utter

TITLE
Principal Financial Officer & Treasurer
COMPENSATION
$871K
AGE
40
TENURE
1.8 yrs

Marcio Souza

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
39
TENURE
1.9 yrs

Neil Almstead

TITLE
Chief Technical Operations Officer
COMPENSATION
$952K
AGE
51
TENURE
0.3 yrs

Mark Boulding

TITLE
Executive VP & Chief Legal Officer
COMPENSATION
$1M
AGE
57
TENURE
7.1 yrs

Mark Rothera

TITLE
Consultant
COMPENSATION
$1M
AGE
55
TENURE
1.7 yrs

Mark Pykett

TITLE
Chief Scientific Officer
AGE
54
TENURE
0.3 yrs

Emily Hill

TITLE
Executive Director of Investor Relations
TENURE
5.4 yrs

Jane Baj

TITLE
Vice President of Corporate Communications
Board of Directors Tenure

Average tenure and age of the Therapeutics board of directors in years:

14.4
Average Tenure
66
Average Age
  • The average tenure for the Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Michael Schmertzler

TITLE
Chairman of the Board
COMPENSATION
$242K
AGE
66
TENURE
14.4 yrs

Stuart Peltz

TITLE
Co-Founder
COMPENSATION
$2M
AGE
58
TENURE
21.3 yrs

Allan Jacobson

TITLE
Co-Founder
COMPENSATION
$223K
AGE
72
TENURE
19.3 yrs

David Southwell

TITLE
Director
COMPENSATION
$157K
AGE
57
TENURE
13.3 yrs

Jody Puglisi

TITLE
Member of Scientific Advisory Board
TENURE
15.4 yrs

Marvin Wickens

TITLE
Member of Scientific Advisory Board

Robert Schneider

TITLE
Member of Scientific Advisory Board

Eric Jacobsen

TITLE
Member of the Scientific Advisory Board
AGE
58

Jerry Zeldis

TITLE
Director
COMPENSATION
$140K
AGE
68
TENURE
6.6 yrs

Glenn Steele

TITLE
Director
COMPENSATION
$138K
AGE
73
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
29. Jan 19 Buy Section Six Partners, L.P. Company 25. Jan 19 25. Jan 19 66,225 €26.47 €1,752,996
09. Jan 19 Sell Stuart Peltz Individual 07. Jan 19 07. Jan 19 -2,512 €30.31 €-76,127
09. Jan 19 Sell Neil Almstead Individual 07. Jan 19 07. Jan 19 -653 €30.31 €-19,789
09. Jan 19 Sell Marcio Souza Individual 07. Jan 19 07. Jan 19 -83 €30.31 €-2,515
09. Jan 19 Sell Christine Utter Individual 07. Jan 19 07. Jan 19 -297 €30.31 €-9,001
04. Jun 18 Sell Marcio Souza Individual 01. Jun 18 01. Jun 18 -5,161 €29.69 €-153,220
X
Management checks
We assess Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Details
Name: PTC Therapeutics, Inc.
P91
Exchange: DB
Founded: 1998
$1,874,182,205
58,401,698
Website: http://www.ptcbio.com
Address: PTC Therapeutics, Inc.
100 Corporate Court,
South Plainfield,
New Jersey, 07080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS PTCT Common Stock Nasdaq Global Select US USD 20. Jun 2013
DB P91 Common Stock Deutsche Boerse AG DE EUR 20. Jun 2013
Number of employees
Current staff
Staff numbers
514
Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:33
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.